Skip to content

“What Do I Tell The Kids?” Workshop


This free workshop focuses on building awareness about how to carry out conversations about cancer diagnosis and treatment. People impacted by cancer and their loved ones are invited to join us as we learn what kids know about this condition at different ages, how to talk about cancer, tips for answering common questions, ways to help your child, and additional resources.

Dinner will be served, and childcare will be provided!                      

Featured speakers include:

·     Abra Kelson, MSW, LICSW

·     Caitlyn Graves, MSW, LSWA-IC

Date: Thursday, March 14, 2019

Time: 6:00 PM – 7:30 PM

Location:  Puyallup United Methodist Church

                   1919 W Pioneer Ave, Puyallup, WA 98371

This is a free program, but registration is required. To register contact, Abra Kelson at (253) 200-3164,

Free Clinical Trials Workshop

This free workshop focuses on building awareness about clinical trials. People impacted by cancer and their loved ones are invited to join us as we learn how these trials are structured, and how to foster an open dialogue with their health care team about the eligibility and the viability of clinical trials as a treatment option. In addition, participants will learn about the importance of shared decision making and will be introduced to resources to help facilitate these conversations.

When: Monday, February 25, 2019 at 5:30 PM-7:00 PM

Where: Best Western Premier Plaza Hotel & Conference Center, Georgian Conference Room
620 South Hill Park Drive, Puyallup, WA 98373

FEATURING: Rohan Sharma, MD

This Is A Free Program, but Registration Is Required. To Register Contact, Abra Kelson at: (253) 200-3164,

Reducing Cancer Costs Through Symptom Management and Triage Pathways



Value-based care infers care that is high quality at a comparatively low total cost. A key strategy for value-based oncology care is to avoid unnecessary emergency room (ER) visits and associated hospitalizations of patients receiving treatment for cancer. Early experience with this strategy showed that symptom managementin patients with cancer can result in the reduction of ER events and hospitalizations. However, quantifying the actual savings achieved has been elusive. In this article, we present the impact of symptom management and triage pathways programs deployed at two midsize community oncology practices.We then quantify the actual dollar saving in their Medicare and commercial populations.


Symptom management records generated through the ER triage programs at the two practices were screened to identify avoided ER events. This approach was validated with an independent analysis using Medicare claim data from the Oncology Care Model program in which both practices participate. Bootstrap simulations were used to test for statistical significance of the ER event rate changes before and after the launch of the program. Average event and annual total cost savings from avoided ER incidents and ER-related hospitalizations were then calculated.


Two hundred twenty-two avoided ER events were identified, for an estimated net annualized savings generated by the two practices of $3.85 million. Although the ER rate reduction was not statistically significant, these findings are consistent with the observed reduction of ER event rates among a subset of Oncology Care Model beneficiaries at the two practices.


ER events and associated hospitalizations can be avoided as well as quantified as a result of the deployment of a practice-level integrated platform that incorporates physician scripted symptom management protocols and telephone triage pathways.


High-value or value-based care refers to care that is high quality at a comparatively low total cost.1 One of the key strategies for delivering oncology care at a relatively low total cost is to avoid unnecessary, unwarranted emergency room(ER) visits and associated hospitalizations of patients undergoing active treatment. This is achievable through deployment of proactive symptom management and triage pathway protocols. Early experience with this strategy reported by others indicated that symptom management in patients with cancer does, in fact, result in the avoidance of unnecessary ER events and associated hospitalizations. The Oncology Patient-Centered Medical Home model of care reported a progressive decline in ER referrals per chemotherapy patient per year and a reduction in associated hospital admissions.2 In a 3-year pilot study conducted by United Healthcare, a cost reduction of $33 million over 3 years was attributed to a decrease in hospitalizations and radiation treatment.3 In an Aetna-Texas oncology pilot study to test the impact of Oncology Medical Home, patients were reported as experiencing 40% fewer ER visits and 16.5% fewer inpatient admissions over the initial 18-month period of the pilot.4 COME HOME (Community Oncology Medical Home), a Center for Medicare and Medicaid Innovation  rant program, showed that the rate of hospital admissions was reduced by 12.5% and ER visits were reduced by 6.6%.5,6 The Oncology Care Model (OCM) program of Center for Medicare and Medicaid Innovation, which was launched in July 2016, also seeks to further demonstrate this cost savings proposition for Medicare beneficiaries.7 These previous studies demonstrate the opportunity to reduce costs of cancer care by focusing on high-cost ER and hospitalization events. However, quantifying the actual dollar amount of savings achieved has been elusive.

The objective of our study was to quantify both the impact and the savings derived from precluding unnecessary ER visits and hospitalizations through a system of symptom management and triage pathway programs deployed at two midsize community oncology practices.The basis of the study was data generated from the two practices over the course of a 6-month period (January 2017 through June 2017).


Study Participants and the ER Triage Program
The Center for Cancer and Blood Disorders (CCBD) in Fort Worth, Texas and Northwest Medical Specialties (NWMS) in Tacoma, Washington were the participating study practices. There are 13 medical oncologists at CCBD and 10 at NWMS. Both practices are in the vanguard of value-based oncology care, and both are participants in OCM.

CCBD and NWMS have implemented a common technology solution, the symptom management and triage pathways platform of Navigating Cancer (Seattle, WA). The technology solution enables nurse triage staff to effectively resolve critical clinical issues and to preclude in many instances what would otherwise have been an unnecessary and avoidable trip to the ER. During the study period, nearly 5,000 patients were served by the platform, which generated over 10,000 care management event tickets.

Identifying the Avoided ER Events
To identify the ER events that were avoided, an evaluation was conducted of the patient communications originated and recorded in the Navigating Cancer symptom management and triage pathways system. The system documents the disposition of patient communications in the form of an electronic ticket. One of the most frequently used ticket categories, the Symptom Ticket, is the tool for tracking clinical interventions in response to patient inquiries. Symptom Tickets ensure that symptoms are managed systematically and consistently across the practice in accordance with physician-vetted triage pathways. Symptom Tickets are designed to track staff response to adverse effect inquiries common to chemotherapy, such as nausea, vomiting, diarrhea, constipation, pain, rash, fever, fatigue, cough, trouble breathing, and swelling or lumps. We determined that the triggering event for an avoided ER event occurred in instances where a patient was routed to the practice for an assessment or intervention of a clinical condition.

To narrow the number of total tickets to a subset in which a response to a critical symptom inquiry had occurred, a keyword search of the “Notes” section of the tickets was conducted. Keywords included the following terms: chest pain, shortness of breath, can’t control, emergency, fever, severe, too much, extreme, hospital, 911, hydrate, fluid, and infuse. The screened tickets were then individually reviewed by an oncology-certified nurse to determine whether the patient had been directed to come to the practice for a clinical assessment or intervention, thus precluding what would otherwise have been an ER event.

Medicare Claims Validation of Avoidable ER Events
As OCM participants, CCBD and NWMS receive from Centers for Medicaid and Medicare Services data that include all medical claims from the Medicare beneficiaries who received chemotherapy between 2012 and 2014(1,499 patients at CCBD and 1,648 patients at NWMS) and from July 1, 2016,to June 30, 2017 (1,157 patients at CCBD and 722 patients at NWMS). More than 30% of the OCM patients at each site had been subjected to ER triage since the triage program started, validating the use of OCM data as an independent source to verify the effect of ER triage program. Because the ER triage program was implemented on January 1, 2017,we used the last 6 months of 2016 as the prior study period to compare with the first 6 months in 2017. Case-mix effects and seasonal variations in ER visits, which could potentially bias the study,we reevaluated using 3 full years of data (2012 to 2014). We used 2017 OCM claims to calculate avoidable ER events and the average Medicare ER and hospitalization costs to estimate the total savings of the program.

Quantifying the Costs of ER and Hospitalization
Avoidance Actual cost for an ER visit should include both the amount paid by Medicare to the facility (usually 80%) and the coinsurance responsibility of the Medicare beneficiary (20% out of pocket or through supplemental insurance).To calculate the total cost of an ER visit, we extracted both Medicare payment and coinsurance payment from the OCM claims data and combined them.

Medicare ER claims data reflect only ER facility costs and do not include any of the other medical costs associated with an ER event, such as laboratory or ER physician professional services.8 To calculate the total costs associated with an ER visit, we identified other ER-related services by matching Part B claims in the OCM data to ER facility claims by patient identification, service time, and place of service, and extracted the allowed payment from those claims to add to the ER facility costs. We also calculated the total costs associated with the hospitalization resulting from an ER visit. In addition, we used the OCM claims to identify the proportion of ER visits that led to a hospitalization to estimate the cost from avoided hospitalizations related to ER triage. Patients who avoid the ER but are redirected to the physician’s office for care incur non ER office visit costs. To address these office-based costs, we calculated an average office visit cost at each site and deducted the amount as an offset to the ER cost to preclude overestimation of savings.

To predict the cost and savings to commercial payers, we used the OCM-reported Medicare claims data with a multiple of Medicare cost. The multiple of Medicare that we applied was 1.75, which is the multiple identified in a 2016 study by America’s Health Insurance Plans.9

Statistical Analysis
Comparable person-time units were created to account for the varying intervals that patients were active in the OCM program. For each OCM patient and in each phase of the study, we counted total cumulative days that the  patient was in the program and ER events that occurred. We defined 6-month ER event rate as the total number of ER visits divided by the total number of days and then multiplied by 183 days. We created the expected ER event rate and reference ER rates using the historical OCM data. The expected ER rate was calculated for each site using 2012 to 2015 Centers for Medicare and Medicaid Services claims data stratified by patient case mix including cancer types, sex, and age groups. We also stratified by quarter to account for the expected seasonal variations in ER visits. Reference ER event rates were also calculated for each site.

The actual case mix and seasonally adjusted ER event rate were calculated separately for the 6-month period before (July to December 2016) and after(January to June 2017) the launch of the symptom management and ER  triage program. The actual ER event rate in each period is divided by the expected ER event rate and multiplied by the reference ER event rate.

To test for statistical significance of the ER event rate changes before and after the launch of program, we used bootstrap simulations because they make the least assumptions of the underlying distribution that describes the data. We ran 5,000 bootstrap simulations and calculated the ER event change in each simulation. To account for the intraclass correlation between ER visits for the same patient, we used patient-clustered sampling during the bootstrap simulations.

For a more stringent evaluation of the hypothesis of a reduction in ER rate, we used two-sided testing. We calculated 95% CIs of the ER event rate change by identifying the 2.5th and 97.5th percentile of the rate difference from the bootstrap distribution. Two-sided P values were also calculated on the basis of bootstrap distribution. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) and were conducted for each site separately.


ER Events Avoided Through Triage Program

A total of 10,417 tickets were generated at the two practices over the 6-month study period, of which 3,909 tickets (38%) were for responses related to symptoms that contained triggering keywords, thus subjecting them to additional evaluation. Of the 3,909 tickets, 284 were identified as critical events that could have resulted in an ER visit, of which 62 were directed to the ER and 222 were directed to the physician’s office for  assessment. ER events were thus avoided for these 222 tickets that received office-based services as an alternative to using the ER. The numbers of avoided Medicare ER events were 45 events for CCBD and 59 events for NWMS (Table 1).

To verify that the projected effect on ER triage was consistent with the actual change in ER event rate before and after the program implementation, we conducted an independent claim-based an alysis on the ER event rate using Medicare OCM data. Between July 1, 2016, and June 30, 2017, 1,157 and 722 unique OCM patients were identified, composing 1,351 and 841 6-month person-time units at CCBD and NWMS, respectively. At CCBD, 480 patients (41%) had at least one ER visit; among these patients, 113 patients (23%) had three or more ER visits, with the latter contributing to 49% of all ER visits. At NWMS, 248 patients (34%) had at least one ER visit, and 51 patients(21%) had three or more ER visits,contributing to 46% of total ER visits. There were no ER frequent users who disproportionately affected the ER visits. Compared with the 6-month period before the triage program started, the risk adjusted ER event rate decreased in the first 6 months of program implementation from 73.0% to 65.8% (7.2% reduction) at CCBD and from 64.7% to 58.3% (6.4% reduction)at NWMS, equivalent to 50 avoided ER events at CCBD and 28 avoided ER events at NWMS over a 6-month period (Table 1). The simulation analysis suggested that the ER changes were directionally correct for reductions for both practices, with CCBD showing a 7.2% reduction and NWMS a 6.4% reduction. However, the two-sided P values from bootstrap simulation were not significant at the P = .05 level (CCBD, P = .09; NWMS, P = .15).

Analysis of the seasonal variations among ER event rate showed that the case mix–adjusted ER event rate is slightly lower (92%) from July to December compared with the rate from January to June. Because our study period is January to June, we estimated that the annual number of avoided ER visits through the triage program would be 426 (222 + [222 X 0.92]), 175 at CCBD and 251 at NWMS.

Average ER and ER-Related Hospitalization Costs

OCM claims data for CCBD and NWMS showed average ER facility costs per Medicare beneficiary of $574 and $671, respectively.The average beneficiary coinsurance costs was $223 and $380 for CCBD and NWMS, respectively. In addition, average Part B payments associated with the ER visit were $399  and $357 for CCBD and NWMS, respectively. Therefore, the average overall cost for an ER visit for a Medicare patient is $1,195 for CCBD and $1,408 for NWMS. After subtracting the additional cost of an office-based visit ($262 for CCBD and $141 for NWMS), the average net reduced costs from avoided ER visits were $933 for CCBD and $1,267 for NWMS. In addition, the Medicare claims data showed average hospitalization costs per beneficiary of $8,849 and $10,932 for CCBD and NWMS, respectively. After adding patient coinsurance obligation($777 and $877 for CCBD and NWMS,respectively) and the associated professional costs ($1,758 and $1,353 for CCBD and NWMS, respectively), the average costs of an ER-related hospitalization for Medicare beneficiaries of CCBD and NWMS were $11,384 and $13,162, respectively (Table 2). With the application of 1.75 as the multiplier, we estimated the average avoided commercial ER costs are $1,632 for CCBD and $2,217 for NWMS and the average avoided commercial ER-related hospitalization costs are $19,921 for CCBD and $23,034 for NWMS.

Table 1. ER Events Avoided Through 6-Month Triage Management and Verified in the OCM Data

ER triage program

No. of all tickets (6-month study period)



No. of tickets containing keywords



No. of tickets identified as critical incidents



No. of patients who went to ER



No. of patients brought to office for assessment or intervention (avoided ER)

No. of commercial patients4672
No. of Medicare patients4559
No. of Medicare OCM patients1820
OCM Program
No. of unique OCM patients1,157722
Total No. of person-time units
(6 months)
Adjusted 6-month ER event rate before triage program
started, %
Adjusted 6-month ER event rate after triage program
started, %
ER incident rate reduction, % (95% CI)7.2 (23.5 to 18)6.4 (25.7 to 19)
No. of ER incidents avoided5028
Two-sided test P.09.15 

Abbreviations: CCBD, Center for Cancer and Blood Disorders; ER, emergency room; NWMS, Northwest Medical Specialties; OCM, Oncology Care Model

Estimation of Total Annual Avoided ER and ER Related Hospitalization Savings
On the basis of the average ER cost for Medicare and commercial payers and the number of avoided ER events identified at each practice, we calculated the total annualized and seasonally adjusted savings from avoided ER events to be $223,854 for CCBD ($80,238 from Medicare and $143,616 from commercial) and $449,117 for NWMS ($143,171 from Medicare and $305,946 from commercial; Table 3).

CCBD and NWMS experienced the similar ER-to hospitalization conversion rate of 43%, and this rate did not change significantly before and after the launch of the symptom management program. Given each practice’s avoided ER events and the ER-to-hospitalization conversion rate, we calculated the likely ER-related hospitalizations that were avoided as a result of ER triage (Table 3). The annualized reduced costs from avoided hospitalization are $1.18 million for CCBD and $2.0 million for NWMS. Our calculation of annual combined (ER and hospitalization) cost savings to all payers that resulted from proactive symptom management and use of triage pathways is $1.40 million at CCBD and $2.45 million at NWMS


Achieving cost savings by avoiding unnecessary, unwarranted ER visits and associated hospitalizations among patients being treated for cancer has been demonstrated in several studies and continues to be tested in a broader context with the increased implementation of value-based care management. Proactive symptom management and triage pathways applications can be an important strategy for achieving this objective. Our study identified reduced ER events and associated hospitalizations as a result of the deployment of a practice-level symptom management and triage pathways program. For two midsize oncology practices that have such programs in place, the resulting total annualized savings ranged from $1.4 million to$2.45 million.

Our projected ER avoidance through the triage data analysis was consistent with the independent claim-based analysis among the Medicare OCM subset of patients. At both sites, we observed a similar 6% to 7% ER event rate reduction over the first 6 months of the program implementation, suggesting the projected numbers from the ER triage program are reliable. The number of reduced ER events in OCM are actually larger than the numbers from the ER triage program, suggesting that other care improvement interventions through the OCM program have also contributed to the overall ER reductions.

Our results are also in alignment with the findings from other cancer management programs, including the Oncology Patient-Centered Medical Home,2 Aetna’s study,4 and the COME HOME program.5,6 The results reported in this study, together with the results of other studies that feature symptom management, all support the significant effect of such interventions in care improvement and cost savings.

When estimating the cost related to ER visits or avoided hospitalizations, most studies report only the facility cost that is paid by Medicare or the commercial payer, rather than the actual total cost,which should also include patient coinsurance and the professional services (eg, physician services, imaging, laboratory) that also occurred during the ER visit and hospital stay.Therefore, the cost related to ER visits and hospitalizations are usually significantly underestimated. In this study, we leveraged the detailed payment information from Medicare OCM claims data to calculate the average cost for each component, thus providing more accurate estimates for the
total costs related to ER visits and hospitalization. Our calculation showed that patient’s responsibility and professional service payment together can account for approximately 50% of ER cost and 20% of hospitalization cost. We recommend that these costs always be included in the financial analysis of medical costs.

We acknowledge certain limitations to the study. First, we have attempted to identify events that did not actually occur, although we are confident that the methodology used to identify the ER nonevents was rigorous and highly reliable.The independent analysis of OCM claims data further verified the validity of this method. More methodological work is required when researching avoidable events to more definitively capture such outcomes. Second, our study consists of a small sample size exacerbated by evaluating small (6% to 7%) changes in ER visits during a short study period(6 months), thus limiting our ability to confirm statistical significance in the reduction in ER events. We used bootstrap simulation to determine 95% CIs and two-sided P values from the sample data, which is a more accurate method to evaluate the stability of our results rather than using standard tests that rely on the assumption of normality.Although our results are not statistically significant, even small reductions in ER visits can have a large financial impact to practices, as we demonstrated in the results, thus providing a strong indication for continuing investigation. We have now rolled the symptom management and triage pathways program out to practices of the Quality Cancer Care Alliance, an oncology-specific clinically integrated network. We intend to further evaluate cost savings generated from this expansion of the program and anticipate that additional study will demonstrate significant savings across multiple practices. Data limitations of the OCM data did not allow for rigorous risk adjustments for patient comorbidities, which can potentially affect findings. Third, we relied on the findings of others to determine the cost ratio of commercial-to-Medicare costs for the same service, which could affect the accuracy of the total savings among commercial patients, but it should not affect the major conclusions of this study. Finally, we recognize that medical practices incur operating expenses in providing their symptom management and triage pathways services and that those operating expenses would be a deduction to any economic gain to the practices resulting from their symptom management services. However, the purpose of our study was to identify and quantify savings in total cost of care and not to measure associated operating costs incurred in providing such services. Further research is warranted with regard to the revenue and expense relationships associated with providing such programs at the practice level.

In conclusion, our analysis has demonstrated that ER events and their associated hospitalization costs can be quantified and potentially mitigated as a result of the deployment of a practice-level symptom management and triage pathways program and that for two midsize oncology practices that have such programs in place, the resulting potential annualized savings generated range from $1.40 million to $2.45 million. Avoiding unnecessary ER visits and associated hospitalizations of patients undergoing active chemotherapy treatment remains a key strategy for delivering high-quality, high-value oncology care at a relatively lower total cost, and we encourage continued research in this area.

Table 2. Average Avoided ER and Hospitalization Costs for Medicare and Commercial Payers


ER Medicare facility payment, $


ER coinsurance and patient responsibility, $


Medicare Part B payment related to ER, $


Total ER cost, Medicare, $


Additional cost for ER alternate office visits, $


ER cost avoided, Medicare, $


Multiple of Medicare cost applied to commercial


ER cost avoided, commercial payers, $

Hospital Medicare facility payment, $8,84910,932
Hospital coinsurance and patient responsibility, $777877
Medicare Part B payment related to hospital stay, $1,7581,353
Total hospitalization cost, Medicare, $11,38413,162
Multiple of Medicare cost applied to commercial1.751.75
Hospitalization cost, commercial payers, $19,92123,034

Abbreviations: CCBD, Center for Cancer and Blood Disorders; ER, emergency room; NWMS, Northwest Medical Specialties

Table 3. Annualized and Seasonally Adjusted ER and Hospitalization Costs Avoided




No. of Medicare ER events avoided



Per ER visit cost avoided, Medicare, $



Total avoided Medicare ER cost (per ER cost avoided
Medicare 3 avoided ER events), $

80,238 143,171
No. of Commercial ER events avoided88138
Per ER visit cost avoided, commercial, $



Total avoided commercialER cost (perER cost avoided
commercial 3 avoided ER events), $

Total ER costs avoided, all payors, $





No. of Medicare hospitalizations avoided


Hospitalization cost, Medicare, $


Medicare hospital costs avoided, $


No. of commercial hospitalizations avoided


Hospitalization cost, commercial, $


Hospital costs avoided, commercial, $


Total hospitalization costs avoided, all payors, $


Total costs avoided (ER + hospital), $


Abbreviations: CCBD, Center for Cancer and Blood Disorders; ER, emergency room; NWMS, Northwest Medical Specialties.


1. Blayney DW, Simon MK, Podtschaske B, et al: Critical lessons from high-value oncology practices. JAMA Oncol 4:164-171, 2018
2. Sprandio JD: Oncology patient-centered medical home and accountable cancer care. Commun Oncol 7:565-572, 2010
3. Newcomer LN, Gould B, Page RD, et al: Changing physician incentives for affordable, quality cancer care: Results of an episode payment model. J Oncol Pract 10: 322-326, 2014
4. Butcher L: How oncologists are bending the cancer cost curve. Oncol Times 35: 5-6, 2013
5. Snaghavi D, Patel K, Samuels K, et al: Transforming cancer care and the role of payment reform: Lessons from the New Mexico Cancer Center.
6. Jenkins K: COME HOME program lowers costs for cancer patients.
7. Center for Medicare and Medicaid Innovation: Oncology Care Model (OCM) request for applications (RFA).
8. Center for Medicare and Medicaid Innovation: Technical Reference Guide for OCM Practice Feedback Reports v3. Baltimore, MD, Centers for Medicare and Medicaid Services, 2017
9. America’s Health Insurance Plans: National Comparison of Commercial and Medicare Fee-For-Service Payments to Hospitals.



Reducing Cancer Costs Through Symptom Management and Triage Pathways

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to or


Ronald Barkley
Consulting or Advisory Role: Cancer Treatment Centers of America
Research Funding: Navigating Cancer

Mah-Jabeen Soobader
Employment: Johnson & Johnson (I)
Stock and Other Ownership Interests: Johnson & Johnson (I)
Patents, Royalties, Other Intellectual Property: Husband holds multiple patents for Johnson & Johnson (I)
Travel, Accommodations, Expenses: Johnson & Johnson (I)

Jun Wang
No relationship to disclose

Sibel Blau
Employment: Northwest Medical Specialties (I)
Leadership: Northwest Medical Specialties
Stock and Other Ownership Interests: Northwest Medical Specialties
Consulting or Advisory Role: Bristol-Myers Squibb
Research Funding: Northwest Medical Specialties
Expert Testimony: Northwest Medical Specialties
Travel, Accommodations, Expenses: Northwest Medical Specialties
Other Relationship: Northwest Medical Specialties, All4Cure (I), Quality Cancer Care Alliance

Ray D. Page
Employment: The Center for Cancer and Blood Disorders
Honoraria: Community Oncology Alliance, AmerisourceBergen
Consulting or Advisory Role: Via Oncology

The Best Foods For Prostate Health

The prostate gland is an integral part of the male reproductive system. About the size of a walnut, it continues to change and grow during a man’s lifetime. Maintaining prostate health should be of maximum importance to all men if they want to lead a long and healthy life.

Let’s look at three medical issues that can arise as a result of the prostate gland, and some recommendations for the best foods for prostate health.

Read article “The Best Foods For Prostate Health”

Why and When Should I Get Screened for Lung Cancer

Your doctor may recommend a lung cancer screening or diagnostic test, but that doesn’t mean he or she thinks you have cancer. If you are at risk for developing lung cancer or have certain symptoms, there are screening tests that can detect cancer early. Getting tests, like chest x-rays or chest CTs, have helped detect cancer and decrease the risk for getting lung cancer.

Read article “Why and When Should I Get Screened for Lung Cancer”

The Importance of Colon Cancer Screenings

As one of the most common forms of cancer for American men and women, colon cancer affects tens of thousands of people each year.

This particular type of cancer takes a significant amount of time to develop, which is why it is so important to receive regular colon cancer screenings. A quick diagnosis and treatment process could mean the difference between life or death of a patient.

Read article “The Importance of Colon Cancer Screenings”